These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 28977680)

  • 1. Effects of the kinase inhibitor sorafenib on heart, muscle, liver and plasma metabolism in vivo using non-targeted metabolomics analysis.
    Jensen BC; Parry TL; Huang W; Beak JY; Ilaiwy A; Bain JR; Newgard CB; Muehlbauer MJ; Patterson C; Johnson GL; Willis MS
    Br J Pharmacol; 2017 Dec; 174(24):4797-4811. PubMed ID: 28977680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-Targeted Metabolomics Analysis of the Effects of Tyrosine Kinase Inhibitors Sunitinib and Erlotinib on Heart, Muscle, Liver and Serum Metabolism In Vivo.
    Jensen BC; Parry TL; Huang W; Ilaiwy A; Bain JR; Muehlbauer MJ; O'Neal SK; Patterson C; Johnson GL; Willis MS
    Metabolites; 2017 Jun; 7(3):. PubMed ID: 28640223
    [No Abstract]   [Full Text] [Related]  

  • 3. Kinome and Transcriptome Profiling Reveal Broad and Distinct Activities of Erlotinib, Sunitinib, and Sorafenib in the Mouse Heart and Suggest Cardiotoxicity From Combined Signal Transducer and Activator of Transcription and Epidermal Growth Factor Receptor Inhibition.
    Stuhlmiller TJ; Zawistowski JS; Chen X; Sciaky N; Angus SP; Hicks ST; Parry TL; Huang W; Beak JY; Willis MS; Johnson GL; Jensen BC
    J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 29051215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sorafenib cardiotoxicity increases mortality after myocardial infarction.
    Duran JM; Makarewich CA; Trappanese D; Gross P; Husain S; Dunn J; Lal H; Sharp TE; Starosta T; Vagnozzi RJ; Berretta RM; Barbe M; Yu D; Gao E; Kubo H; Force T; Houser SR
    Circ Res; 2014 May; 114(11):1700-1712. PubMed ID: 24718482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. STAT3-mediated attenuation of CCl4-induced mouse liver fibrosis by the protein kinase inhibitor sorafenib.
    Deng YR; Ma HD; Tsuneyama K; Yang W; Wang YH; Lu FT; Liu CH; Liu P; He XS; Diehl AM; Gershwin ME; Lian ZX
    J Autoimmun; 2013 Oct; 46():25-34. PubMed ID: 23948302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-proliferative but not anti-angiogenic tyrosine kinase inhibitors enrich for cancer stem cells in soft tissue sarcoma.
    Canter RJ; Ames E; Mac S; Grossenbacher SK; Chen M; Li CS; Borys D; Smith RC; Tellez J; Sayers TJ; Monjazeb AM; Murphy WJ
    BMC Cancer; 2014 Oct; 14():756. PubMed ID: 25301268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rho-kinase-dependent pathway mediates the hepatoprotective effects of sorafenib against ischemia/reperfusion liver injury in rats with nonalcoholic steatohepatitis.
    Yang YY; Huang YT; Lee TY; Chan CC; Yeh YC; Lee KC; Lin HC
    Liver Transpl; 2012 Nov; 18(11):1371-83. PubMed ID: 22847887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.
    Lachenmayer A; Alsinet C; Savic R; Cabellos L; Toffanin S; Hoshida Y; Villanueva A; Minguez B; Newell P; Tsai HW; Barretina J; Thung S; Ward SC; Bruix J; Mazzaferro V; Schwartz M; Friedman SL; Llovet JM
    Clin Cancer Res; 2012 Sep; 18(18):4997-5007. PubMed ID: 22811581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NMR-Based Metabolic Profiling Reveals Neurochemical Alterations in the Brain of Rats Treated with Sorafenib.
    Du C; Shao X; Zhu R; Li Y; Zhao Q; Fu D; Gu H; Kong J; Luo L; Long H; Deng P; Wang H; Hu C; Zhao Y; Cen X
    Neurotox Res; 2015 Nov; 28(4):290-301. PubMed ID: 26233726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinct behaviour of sorafenib in experimental cachexia-inducing tumours: the role of STAT3.
    Toledo M; Penna F; Busquets S; López-Soriano FJ; Argilés JM
    PLoS One; 2014; 9(12):e113931. PubMed ID: 25436606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
    Singh AR; Joshi S; Burgoyne AM; Sicklick JK; Ikeda S; Kono Y; Garlich JR; Morales GA; Durden DL
    Mol Cancer Ther; 2016 Nov; 15(11):2553-2562. PubMed ID: 27496136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sorafenib enhances proteasome inhibitor-induced cell death via inactivation of Akt and stress-activated protein kinases.
    Honma Y; Shimizu S; Takehara T; Harada M
    J Gastroenterol; 2014 Mar; 49(3):517-26. PubMed ID: 23543326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological evaluation of a novel sorafenib analogue, t-CUPM.
    Wecksler AT; Hwang SH; Liu JY; Wettersten HI; Morisseau C; Wu J; Weiss RH; Hammock BD
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):161-71. PubMed ID: 25413440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic interaction between the HDAC inhibitor, MPT0E028, and sorafenib in liver cancer cells in vitro and in vivo.
    Chen CH; Chen MC; Wang JC; Tsai AC; Chen CS; Liou JP; Pan SL; Teng CM
    Clin Cancer Res; 2014 Mar; 20(5):1274-1287. PubMed ID: 24520095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel preclinical strategy for identifying cardiotoxic kinase inhibitors and mechanisms of cardiotoxicity.
    Cheng H; Kari G; Dicker AP; Rodeck U; Koch WJ; Force T
    Circ Res; 2011 Dec; 109(12):1401-9. PubMed ID: 21998323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status.
    Broecker-Preuss M; Müller S; Britten M; Worm K; Schmid KW; Mann K; Fuhrer D
    BMC Cancer; 2015 Mar; 15():184. PubMed ID: 25879531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AKT is critically involved in the antagonism of BRAF inhibitor sorafenib against dabrafenib in colorectal cancer cells harboring both wild-type and mutant (V600E) BRAF genes.
    Wang H; Quan H; Lou L
    Biochem Biophys Res Commun; 2017 Jul; 489(1):14-20. PubMed ID: 28536078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic interactions between sorafenib and everolimus in pancreatic cancer xenografts in mice.
    Pawaskar DK; Straubinger RM; Fetterly GJ; Hylander BH; Repasky EA; Ma WW; Jusko WJ
    Cancer Chemother Pharmacol; 2013 May; 71(5):1231-40. PubMed ID: 23455452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and activator of transcription 3 inhibition.
    Su TH; Shiau CW; Jao P; Liu CH; Liu CJ; Tai WT; Jeng YM; Yang HC; Tseng TC; Huang HP; Cheng HR; Chen PJ; Chen KF; Kao JH; Chen DS
    Proc Natl Acad Sci U S A; 2015 Jun; 112(23):7243-8. PubMed ID: 26039995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leukocyte trafficking is not affected by multikinase inhibitors sunitinib or sorafenib in mice.
    Laurila JP; Laukkanen MO; Joensuu H; Salmi M; Jalkanen S
    Int J Cancer; 2016 Nov; 139(10):2270-6. PubMed ID: 27459381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.